1. Home
  2. SNTI vs TPCS Comparison

SNTI vs TPCS Comparison

Compare SNTI & TPCS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SNTI
  • TPCS
  • Stock Information
  • Founded
  • SNTI 2016
  • TPCS 1956
  • Country
  • SNTI United States
  • TPCS United States
  • Employees
  • SNTI N/A
  • TPCS N/A
  • Industry
  • SNTI Biotechnology: Pharmaceutical Preparations
  • TPCS Metal Fabrications
  • Sector
  • SNTI Health Care
  • TPCS Industrials
  • Exchange
  • SNTI Nasdaq
  • TPCS Nasdaq
  • Market Cap
  • SNTI 53.6M
  • TPCS 51.4M
  • IPO Year
  • SNTI N/A
  • TPCS N/A
  • Fundamental
  • Price
  • SNTI $2.15
  • TPCS $4.51
  • Analyst Decision
  • SNTI Strong Buy
  • TPCS
  • Analyst Count
  • SNTI 3
  • TPCS 0
  • Target Price
  • SNTI $9.67
  • TPCS N/A
  • AVG Volume (30 Days)
  • SNTI 327.7K
  • TPCS 31.1K
  • Earning Date
  • SNTI 11-13-2025
  • TPCS 08-21-2025
  • Dividend Yield
  • SNTI N/A
  • TPCS N/A
  • EPS Growth
  • SNTI N/A
  • TPCS N/A
  • EPS
  • SNTI N/A
  • TPCS N/A
  • Revenue
  • SNTI N/A
  • TPCS $33,424,000.00
  • Revenue This Year
  • SNTI N/A
  • TPCS N/A
  • Revenue Next Year
  • SNTI $150.00
  • TPCS N/A
  • P/E Ratio
  • SNTI N/A
  • TPCS N/A
  • Revenue Growth
  • SNTI N/A
  • TPCS 3.78
  • 52 Week Low
  • SNTI $1.26
  • TPCS $2.05
  • 52 Week High
  • SNTI $16.94
  • TPCS $6.25
  • Technical
  • Relative Strength Index (RSI)
  • SNTI 62.17
  • TPCS 37.54
  • Support Level
  • SNTI $1.92
  • TPCS $4.60
  • Resistance Level
  • SNTI $2.29
  • TPCS $5.23
  • Average True Range (ATR)
  • SNTI 0.25
  • TPCS 0.34
  • MACD
  • SNTI 0.01
  • TPCS -0.07
  • Stochastic Oscillator
  • SNTI 55.06
  • TPCS 0.94

About SNTI Senti Biosciences Inc.

Senti Biosciences Inc is a clinical-stage biotechnology company developing next-generation cell and gene therapies engineered with its gene circuit platform technologies for patients living with incurable diseases. The product candidates utilize allogeneic chimeric antigen receptor natural killer (CAR-NK) cells outfitted with its gene circuit technologies in various oncology indications. The company product candidates include SENTI-202, a Logic Gated off-the-shelf CAR-NK cell therapy designed to target and eliminate cancer cells while sparing the healthy bone marrow; and SENTI-301A for the treatment of hepatocellular carcinoma.

About TPCS TechPrecision Corporation Common stock

Techprecision Corp manufactures metal fabricated and machined precision components and systems. It offers a full range of services required to transform raw materials into precision finished products. The company's products are used in markets including defense, aerospace, nuclear, medical, and precision industries. All of its operations and customers are located in the United States. The company have two wholly owned subsidiaries that are each reportable segments: Ranor and Stadco. Each reportable segment focuses on the manufacture and assembly of specific components. It derives maximum revenue from Ranor segment.

Share on Social Networks: